Results 171 to 180 of about 266,111 (303)

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

British Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić, Elvira Meni Maria Gkrinia, Patrick Eustaquio, Andrea Katrin Faour, Dinko Vitezić   +4 more
wiley   +1 more source

Cost-effectiveness analysis of Canada's National Overdose Response Service. [PDF]

BMJ Open
Rioux W, Enns B, Viste D, Ghosh SM.
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Cost-consequence analysis of a digital health-enabled non-communicable disease management intervention in Ghana. [PDF]

Cost Eff Resour Alloc
Obeng AA, Bonney RA, Essel TYA, Wilberforce PAG, Agyei-Baffour P.   +4 more
europepmc   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Comparing Different As-Treated Approaches: A Methodological Study Using Real-World Data on Psoriasis Treatments. [PDF]

Pharmacoepidemiol Drug Saf
Kim S, Jensen A, Egeberg A, Stensballe LG.   +3 more
europepmc   +1 more source

A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials

British Journal of Clinical Pharmacology, EarlyView.
Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner, Daniela Krepper, Micha Johannes Pilz, Lisa Marie Storz, Maike Thumfart, Johannes Maria Giesinger   +5 more
wiley   +1 more source

Key Features of Contemporary Pilot and Feasibility Trials: Protocol for a Methodological Study. [PDF]

Acta Anaesthesiol Scand
Tøgern A, Møller MH, Perner A, Kjær MN, Eck RJ, Anthon CT, Barakji JA, Granholm A.   +7 more
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Phase II randomized controlled trial comparing traditional Thai cannabis-based medicine with lorazepam for insomnia treatment. [PDF]

J Cannabis Res
Kamoltham T, Chokchaisiri S, Yongram C, Sripan P, Im-Iam S, Sanasit P, Intaravattana V, Sawasdichai C, Udompat P, Chaiphongpachara T, Kummalue T.   +10 more
europepmc   +1 more source